Phaseline

Companies › VM Discovery

VM Discovery: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2031.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VMD-102
PKC epsilon (PKCε) kinase inhibitor
PRKCEPhase 1Hepatocellular Carcinoma (HCC)May 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07636785VMD-102Phase 1Hepatocellular Carcinoma (HCC)OncologyMay 2031

Targets

PRKCE (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.